Pancreatic cancer is a recalcitrant disease that has been resistant to the development of effective therapeutic strategies that significantly impact survival. With only 4% of pancreatic cancer patients entering on clinical trials, and pancreatic cancer predicted to become the second leading cause of cancer death by 2020, a new paradigm to tackle this disease is needed.
One example of such an approach is Precision Promise, a new national consortium launched in a partnership between academia and the Pancreatic Cancer Action Network. Precision Promise is a multi-armed, adaptive platform trial focused on developing a novel model of cooperation between researchers, clinicians, and industry to accelerate the pace at which the most promising science is driven into the clinical trial setting. Important components of the platform trial include deep analysis of each patient tumor before and during treatment, biomarker development, access to multiple treatment options for each patient, and close alignment with the FDA to push innovation in clinical trial design. In the presentation, the challenges and opportunities of such an effort in pancreatic cancer will be discussed.